StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
1463
This month
6
This week
3
This year
23
Publishing Date
2024 - 04 - 15
3
2024 - 04 - 09
1
2024 - 04 - 08
1
2024 - 04 - 01
1
2024 - 03 - 28
1
2024 - 03 - 15
1
2024 - 03 - 14
1
2024 - 03 - 11
1
2024 - 03 - 06
2
2024 - 03 - 05
1
2024 - 02 - 29
1
2024 - 02 - 26
1
2024 - 02 - 20
1
2024 - 02 - 13
1
2024 - 02 - 12
2
2024 - 02 - 06
1
2024 - 02 - 04
1
2024 - 01 - 22
1
2024 - 01 - 02
1
Sector
Commercial services
1
Health technology
13
Manufacturing
3
Tags
Acquisition
685
Advanced
218
Agreement
489
America
217
Biopharma
225
Business
919
Cancer
350
Ceo
302
Companies
245
Company
513
Conference
2496
Corporation
788
Deadline
504
Distribution
228
Earnings
245
Energy
702
Events
292
Fda
349
Financial
3132
First
1681
For
665
Global
1513
Grants
243
Group
782
Growth
1000
Health
455
International
389
Key
385
Life
249
Management
381
Market
2655
Medical
377
Meeting
556
Million
1217
N/a
28286
Nasdaq
519
Offering
648
One
242
Partnership
309
Pharma
220
Pharmaceuticals
586
Platform
281
Program
421
Reach
490
Report
1901
Research
833
Results
4320
Revenue
275
Services
401
Set
317
Solutions
426
Spac
230
Study
357
System
284
Technology
609
Therapeutics
1189
Treatment
440
Trial
439
Update
908
Year
2881
Entities
89bio, inc.
1
Abbvie inc.
1
Alnylam pharmaceuticals, inc.
2
Altimmune, inc.
1
Arrival
1
Astellas pharma inc
1
Better therapeutics inc
2
Bristol-myers squibb company
1
Can-fite biopharma ltd
2
Cymabay therapeutics inc.
1
Eli lilly and company
1
Galmed pharmaceuticals ltd.
1
Gilead sciences, inc.
2
Hepion pharmaceuticals, inc.
1
Madrigal pharmaceuticals, inc.
4
Metacrine, inc.
1
Mink therapeutics, inc.
3
Nano-x imaging ltd
1
Nuwellis inc
1
Ocean biomedical inc
2
Omniab inc
1
Organovo holdings, inc.
1
Pliant therapeutics, inc.
1
Sanofi
1
Surrozen inc
1
Zealand pharma a/s
1
Symbols
ABBV
1
ALNY
2
ALPMF
1
ALPMY
1
ALT
1
ARVL
1
BMY
1
BTTX
2
CANF
2
CBAY
1
ETNB
1
GILD
2
GLMD
1
HEPA
1
INKT
3
LLY
1
MDGL
4
MTCR
1
NNOX
1
NUWE
1
OABI
1
OCEA
2
ONVO
1
PLRX
1
SNY
1
SNYNF
1
SRZN
1
ZEAL
1
Exchanges
Amex
2
Nasdaq
21
Nyse
2
Crawled Date
2024 - 04 - 15
3
2024 - 04 - 09
1
2024 - 04 - 08
1
2024 - 04 - 01
1
2024 - 03 - 28
1
2024 - 03 - 15
1
2024 - 03 - 14
1
2024 - 03 - 11
1
2024 - 03 - 06
2
2024 - 03 - 05
1
2024 - 02 - 29
1
2024 - 02 - 26
1
2024 - 02 - 20
1
2024 - 02 - 13
1
2024 - 02 - 12
2
2024 - 02 - 06
1
2024 - 02 - 05
1
2024 - 01 - 22
1
2024 - 01 - 02
1
Crawled Time
00:00
2
07:00
1
12:00
2
12:30
2
13:00
7
14:00
3
14:30
1
15:30
1
17:00
1
20:00
2
22:00
1
Source
www.biospace.com
7
www.globenewswire.com
12
www.prnewswire.com
4
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
published :
This year
tags :
Liver
save search
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
Published:
2024-04-15
(Crawled : 13:00)
- biospace.com/
OABI
|
$4.615
0.55%
140K
|
|
-5.35%
|
O:
-1.58%
H:
1.77%
C:
-0.4%
drug
liver
disease
antibody
for
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
Published:
2024-04-15
(Crawled : 13:00)
- biospace.com/
CANF
|
$1.96
-0.51%
650
|
Health Technology
|
-6.19%
|
O:
4.76%
H:
0.45%
C:
-5.91%
drug
candidate
liver
cancer
treat
namodenoson
advanced
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
Published:
2024-04-15
(Crawled : 12:00)
- globenewswire.com
ONVO
|
$1.18
2.61%
98K
|
Health Technology
|
10.88%
|
O:
64.34%
H:
4.82%
C:
-18.67%
fxr314
metabolic
liver
positive
for
results
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
Published:
2024-04-09
(Crawled : 12:00)
- globenewswire.com
MDGL
|
$224.625
1.06%
11K
|
Health Technology
|
-9.72%
|
O:
2.12%
H:
0.7%
C:
-0.82%
liver
treatment
fibrosis
pharmaceuticals
for
advanced
nash
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
Published:
2024-04-08
(Crawled : 17:00)
- globenewswire.com
INKT
|
$0.8717
2.6K
|
|
-41.03%
|
O:
1.28%
H:
0.0%
C:
-16.46%
nk-215
liver
cancer
preclinical
therapeutics
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
Published:
2024-04-01
(Crawled : 12:30)
- globenewswire.com
SRZN
|
$9.33
3
|
|
-40.42%
|
O:
-8.98%
H:
4.61%
C:
-29.37%
szn-043
liver
Promising First-In-Human Phase 1B Clinical Study Data from VRON-0200, a Novel, First-in-Class Checkpoint Modifier Immunotherapy for Chronic Hepatitis B Virus Functional Cure, Presented as Late-Breaker at 2024 APASL Global Liver Meeting
Published:
2024-03-28
(Crawled : 00:00)
- prnewswire.com
OCEA
|
$1.83
-2.4%
56K
|
|
-56.16%
|
O:
0.49%
H:
0.0%
C:
-7.23%
vron-0200
hepatitis
liver
global
immunotherapy
meeting
virus
study
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis
Published:
2024-03-15
(Crawled : 13:00)
- prnewswire.com
GLMD
|
$0.3787
3.1K
|
Health Technology
|
6.02%
|
O:
17.48%
H:
0.0%
C:
-25.59%
mgl-3196
patent
liver
treatment
fibrosis
grant
aramchol
nash
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
Published:
2024-03-14
(Crawled : 20:00)
- globenewswire.com
MDGL
|
$224.625
1.06%
11K
|
Health Technology
|
-8.75%
|
O:
20.66%
H:
2.07%
C:
-8.01%
fda
liver
approval
treatment
fibrosis
pharmaceuticals
advanced
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
Published:
2024-03-11
(Crawled : 12:30)
- biospace.com/
CANF
|
$1.96
-0.51%
650
|
Health Technology
|
-10.86%
|
O:
-0.45%
H:
2.27%
C:
2.27%
europe
liver
conference
distribution
pancreatic
treatment
namodenoson
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
Published:
2024-03-06
(Crawled : 14:00)
- globenewswire.com
INKT
|
$0.8717
2.6K
|
|
-6.12%
|
O:
1.02%
H:
0.48%
C:
-1.41%
nk-215
liver
cancer
preclinical
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024MiNK-215 Eradicated Tumor Cells in Human Organoid MSS Colorectal Cancer Liver Metastases Model
Published:
2024-03-06
(Crawled : 14:00)
- biospace.com/
INKT
|
$0.8717
2.6K
|
|
-6.12%
|
O:
1.02%
H:
0.48%
C:
-1.41%
nk-215
liver
cancer
tumor
preclinical
Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis
Published:
2024-03-05
(Crawled : 13:00)
- globenewswire.com
MDGL
|
$224.625
1.06%
11K
|
Health Technology
|
-9.86%
|
O:
-0.86%
H:
2.04%
C:
1.66%
liver
authorization
treatment
fibrosis
pharmaceuticals
ema
application
Ocean Biomedical (NASDAQ: OCEA) Announces Joint Venture Partner, Virion Therapeutics to Present Their First Clinical Study Data as an Accepted Late Breaker Presentation at 2024 APASL Global Liver Meeting
Published:
2024-02-29
(Crawled : 13:00)
- globenewswire.com
OCEA
|
$1.83
-2.4%
56K
|
|
15.58%
|
O:
2.6%
H:
36.71%
C:
11.39%
first
liver
presentation
global
meeting
therapeutics
study
Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
Published:
2024-02-26
(Crawled : 07:00)
- globenewswire.com
ZEAL
|
$17.59
1.21%
-4.21%
|
Health Technology
|
Email alert
Add to watchlist
pharma
liver
disease
fibrosis
trial
results
Better Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease
Published:
2024-02-20
(Crawled : 15:30)
- biospace.com/
BTTX
|
$0.009
180K
|
|
-95.42%
|
O:
7.55%
H:
2.13%
C:
-27.83%
fda
device
liver
disease
designation
therapeutics
advanced
platform
Nanox Receives FDA Clearance for HealthFLD, an Advanced AI-Based Software Empowering Clinicians in Assessment of Fatty Liver
Published:
2024-02-13
(Crawled : 13:00)
- globenewswire.com
NNOX
|
$9.13
0.66%
190K
|
Health Technology
|
36.6%
|
O:
-6.78%
H:
2.42%
C:
-3.55%
fda
liver
software
clearance
advanced
Liver Disease Therapeutics Competitive Landscape and Market Forecasts to 2028
Published:
2024-02-12
(Crawled : 20:00)
- prnewswire.com
ALPMY
|
$9.47
520K
|
Manufacturing
|
-13.68%
|
O:
0.37%
H:
0.74%
C:
0.28%
BMY
|
$48.295
-0.01%
920K
|
Health Technology
|
-2.91%
|
O:
-0.18%
H:
0.48%
C:
-1.91%
ABBV
|
News
|
$165.09
0.26%
760K
|
Health Technology
|
-4.57%
|
O:
0.8%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.135
1.64%
270K
|
Health Technology
|
-1.49%
|
O:
-0.06%
H:
0.0%
C:
0.0%
GILD
|
News
|
$66.52
0.54%
780K
|
Health Technology
|
-10.14%
|
O:
0.32%
H:
0.11%
C:
-1.55%
ALNY
|
News
|
$146.2
0.72%
39K
|
Health Technology
|
-14.28%
|
O:
-2.63%
H:
0.98%
C:
-1.75%
liver
disease
therapeutics
market
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
Published:
2024-02-12
(Crawled : 14:30)
- biospace.com/
GILD
|
News
|
$66.52
0.54%
780K
|
Health Technology
|
-9.19%
|
O:
-0.35%
H:
2.36%
C:
1.42%
CBAY
|
$32.48
0.03%
8.4M
|
Health Technology
|
30.09%
|
O:
27.92%
H:
0.97%
C:
0.88%
liver
acquisition
sciences
therapeutics
New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload
Published:
2024-02-06
(Crawled : 14:00)
- globenewswire.com
NUWE
|
$0.2644
1.54%
76K
|
Manufacturing
|
-41.67%
|
O:
6.25%
H:
0.78%
C:
-12.75%
aquadex
liver
disease
series
potential
therapy
← Previous
1
2
Next →
Gainers vs Losers
83%
17%
Top 10 Gainers
AGBA
|
News
|
$1.37
242.5%
76M
|
Finance
EGOX
|
$0.0835
131.94%
160M
|
ZCMD
|
$2.18
50.35%
24M
|
Commercial Services
CHRO
|
$1.73
41.22%
46K
|
n/a
RWOD
|
$10.61
32.68%
5.1M
|
n/a
NVFY
|
$2.77
31.28%
2.2M
|
Consumer Durables
AULT
|
$0.3174
31.1%
28M
|
Manufacturing
WISA
4
|
$7.11
20.71%
4.7M
|
Electronic Technology
LIFW
|
News
|
$0.99
19.26%
800K
|
Administrative and Support and ...
PRTG
|
$0.285
18.75%
140K
|
Mining, Quarrying, and Oil and ...
Your saved searches
Save your searches and get alerts when important news are released.